索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]陈钰,肖潇,马雄.自身免疫性肝炎相关肝硬化的研究进展[J].国际消化病杂志,2024,03:141-145.
点击复制

自身免疫性肝炎相关肝硬化的研究进展(PDF)

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:
2024年03期
页码:
141-145
栏目:
综述
出版日期:
2024-06-25

文章信息/Info

Title:
-
作者:
陈钰; 肖潇; 马雄
200001 上海交通大学医学院附属仁济医院消化内科 上海市消化疾病研究所
Author(s):
-
关键词:
自身免疫性肝炎; 肝硬化; 无创评估; 门脉高压; 免疫抑制
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2024.03.001
文献标识码:
-
摘要:
自身免疫性肝炎（AIH）是一种由自身免疫介导的慢性肝脏疾病。AIH的临床表现多样，约33%的AIH患者伴有肝硬化。多项研究表明，肝硬化是影响AIH患者预后的独立危险因素。伴有肝硬化的AIH患者生存期较短且罹患肿瘤的风险较高。肝脏活体组织检查是诊断AIH相关肝硬化的金标准，肝脏瞬时弹性成像检测、血清学标志物检测等可辅助诊断AIH相关肝硬化。对于代偿期AIH相关肝硬化患者，国内外指南均推荐采取免疫抑制治疗，接受治疗后部分患者的肝纤维化可得到逆转，而对于失代偿期AIH相关肝硬化患者是否需要接受免疫抑制治疗尚存争议。该文就AIH相关肝硬化的研究进展作一综述。
Abstract:
-

参考文献/References

1 Lv T, Li M, Zeng N, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population[J]. J Gastroenterol Hepatol, 2019, 34(10): 1676-1684.
2Wang G, Tanaka A, Zhao H, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis[J]. Hepatol Int, 2021, 15(2): 223-257.
3Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722.
4European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis[J]. J Hepatol, 2015, 63(4):971-1004.
5Trivedi PJ, Hirschfield GM. Recent advances in clinical practice:epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70(10):1989-2003.
6Li Y, Yan L, Wang R, et al. Serum immunoglobulin G levels predict biochemical and histological remission of autoimmune hepatitis type 1: a single-center experience and literature review[J]. Clin Rev Allergy Immunol, 2022, 62(2): 292-300.
7Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly[J]. Aliment Pharmacol Ther, 2014, 39(2): 117-124.
8Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938.
9Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176.
10 Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335.
11 Hartl J, Denzer U, Ehlken H, et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis[J]. J Hepatol, 2016, 65(4): 769-775.
12 Janik MK, Kruk B, Szczepankiewicz B, et al. Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis[J]. Liver Int, 2021, 41(2): 348-356.
13 Xu Q, Sheng L, Bao H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis[J]. J Gastroenterol Hepatol, 2017, 32(3): 639-644.
14 Llovet LP, Gratacós-Ginès J, Téllez L, et al. Noninvasive prediction of outcomes in autoimmune hepatitis-related cirrhosis[J]. Hepatol Commun, 2022, 6(6): 1392-1402.
15 Zeng T, Yu J, Tan L, et al. Noninvasive indices for monitoring disease course in Chinese patients with autoimmune hepatitis[J]. Clin Chim Acta, 2018, 486: 135-141.
16 Dong B, Chen Y, Lyu G, et al. Aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in patients with autoimmune hepatitis: a meta-analysis[J]. Front Immunol, 2022, 13: 892454.
17 Guo L, Zheng L, Hu L, et al. Transient elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients[J]. Med Sci Monit, 2017, 23: 5106-5112.
18 de Franchis R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752.
19 Abraldes JG, Bureau C, Stefanescu H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study[J]. Hepatology, 2016, 64(6): 2173-2184.
20 Augustin S, Pons M, Maurice JB, et al. Expanding the Baveno Ⅵcriteria for the screening of varices in patients with compensated advanced chronic liver disease [J]. Hepatology, 2017, 66(6): 1980-1988.
21 de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ- Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. 22 Li YN, Ma H, Zhou L, et al. Autoimmune hepatitis-related cirrhosis:clinical features and effectiveness of immunosuppressive treatment in Chinese patients[J]. Chin Med J (Engl), 2016, 129(20): 2434-2440.
23 Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC[J]. World J Gastroenterol, 2003, 9(12): 2681-2685.
24 Fan X, Yin D, Men R, et al. NUDT15 polymorphism confer increased susceptibility to thiopurine-induced leukopenia in patients with autoimmune hepatitis and related cirrhosis[J]. Front Pharmacol, 2019, 10: 346.
25 Wang Z, Sheng L, Yang Y, et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review[J]. Clin Rev Allergy Immunol, 2017, 52(3): 424-435.
26 Sharma S, Agarwal S, Kaushal K, et al. Presence and type of decompensation affects outcomes in autoimmune hepatitis upon treatment with corticosteroids[J]. JGH Open, 2020, 5(1): 81-90.
27 Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Hepatology, 2014, 59(3): 1144-1165.
28 Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis[J]. Gastroenterology, 1996, 110(3): 848-857.
29 Ngu JH, Gearry RB, Frampton CM, et al. Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study[J]. Hepatology, 2013, 57(6): 2399-2406.
30 Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome[J]. Hepatology, 2005, 42(1): 53-62.
31 Al-Chalabi T, Underhill JA, Portmann BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis[J]. J Hepatol, 2008, 48(1): 140-147.
32 Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center[J]. Gastroenterology, 2011, 140(7): 1980-1989.
33 van den Brand FF, van der Veen KS, de Boer YS, et al. Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2019, 17(5): 940-947. e2.
34 Sharma R, Verna EC, S?derling J, et al. Increased mortality risk in autoimmune hepatitis: a nationwide population-based cohort study with histopathology[J]. Clin Gastroenterol Hepatol, 2021, 19(12):2636-2647. e13.
35 Biewenga M, Verhelst X, Baven-Pronk M, et al. Aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: a landmark analysis[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1776-1783. e4.
36 Gr?nbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark:incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study[J]. J Hepatol, 2014, 60(3): 612-617.
37 Jensen MD, Jepsen P, Vilstrup H, et al. Increased cancer risk in autoimmune hepatitis: a Danish nationwide cohort study[J]. Am J Gastroenterol, 2022, 117(1): 129-137.
38 Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis[J]. J Hepatol, 1993, 18(1): 15-23.
39 Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis[J]. Ann Intern Med, 1997, 127(11): 981-985.
40 Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis[J]. J Hepatol, 2004, 40(4): 646-652.
41 Tonon M, Balcar L, Semmler G, et al. Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event[J]. Hepatology, 2023, 78(4):1149-1158.
42 Wang Q, Zhao H, Deng Y, et al. Validation of Baveno Ⅶ criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77(6): 1564-1572.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（82070583）
通信作者：马雄，Email: maxiongmd@hotmail.com
更新日期/Last Update: 2024-06-25